本文已被:浏览 337次 下载 188次
Received:November 28, 2025 Published Online:August 25, 2026
Received:November 28, 2025 Published Online:August 25, 2026
中文摘要: 距骨骨软骨损伤(OLT)是踝关节疼痛和功能障碍的常见原因。微创与注射治疗作为连接保守治疗与开放手术的重要治疗方式,在OLT的阶梯式治疗体系中发挥着重要作用。目前,微创治疗主要包括关节镜下微骨折术、自体骨软骨移植、逆行钻孔等技术;注射治疗主要包括富血小板血浆、干细胞、透明质酸等生物制剂。不同治疗方式适用于不同分级、大小、深度及稳定性的病灶,合理选择适应证是获得良好疗效的关键。本文就微创与注射治疗的作用机制、适应证选择及临床研究进展进行综述,旨在为OLT的个体化精准治疗提供参考依据。
Abstract:Osteochondral lesions of the talus(OLT)are a common cause of ankle pain and functional impairment. As important therapeutic approaches bridging conservative treatment and open surgery,minimally invasive and injectable therapies play an important role in the stepwise treatment of OLT. Currently,minimally invasive therapies mainly include arthroscopic microfracture,osteochondral autograft transplantation,and retrograde drilling,whereas injectable therapies mainly include biological agents such as platelet-rich plasma,stem cells,and hyaluronic acid. Different treatment modalities are applicable to lesions with diverse grades, sizes, depths and stabilities, and rational selection of indications is critical for achieving favorable therapeutic outcomes.This review summarizes the mechanisms of action,indication selection,and clinical research progress of minimally invasive and injectable therapies,aiming to provide a reference for individualized precision treatment of OLT.
keywords: Osteochondral lesions of the talus Minimally invasive therapy Injectable therapy Arthroscopic technique Platelet-rich plasma Biological agents Hyaluronic acid Stem cell
文章编号: 中图分类号:R687.3 文献标志码:A
基金项目:澳门科技发展基金项目(0018/2024/RIA10114/2022/A)
引用文本:
